Acute hemodynamic changes during intravenous dipyridamole thallium imaging early after infarction.
In order to determine the safety and hemodynamic effects of intravenous dipyridamole infusion for thallium-201 scinitigraphy in patients with acute ischemic syndromes, 10 patients with recent uncomplicated myocardial infarction (7 +/- 2 days pre-test) had central pressures and cardiac output values measured serially in a coronary care unit during and after the administration of dipyridamole (0.56 mg/kg over 4 minutes) and following aminophylline reversal (50 to 150 mg intravenously) of dipyridamole effect. Cardiac medications were not discontinued. Double product did not change significantly (8522 +/- 1811 versus 9044 +/- 1701; p = NS). Serious ischemic events did not occur, although 20% of patients had noncardiac side effects and 30% developed greater than or equal to 1 mm ST segment depression with associated angina in one-third of these cases. The peripheral blood pressure and heart rate response did not predict the occurrence of myocardial ischemia. Dipyridamole significantly reduced systemic vascular resistance (1218 +/- 302 to 739 +/- 166 dyne/sec-1/cm-5; p less than 0.05) and increased cardiac index (3.1 +/- 0.7 to 4.7 +/- 1.0 L/min/m2; p less than 0.05) within approximately 10 minutes, in association with a significant increase in pulmonary capillary wedge pressure (13 +/- 5 to 17 +/- 6 mm Hg; p less than 0.05). Three patients developed silent new "V" waves in their pulmonary capillary wedge pressure tracing, associated with anterior thallium redistribution. All three patients with newly elevated wedge pressures (greater than 15 mm Hg) had both thallium-201 redistribution and multivessel coronary disease.(ABSTRACT TRUNCATED AT 250 WORDS)
Miller
D D
DD
University of Texas Health Science Center, San Antonio 78284.
Scott
R A
RA
Riesmeyer
J S
JS
Chaudhuri
T K
TK
Blumhardt
R
R
Boucher
C A
CA
O'Rourke
R A
RA
D000628:Aminophylline / Q000494:pharmacology; D004176:Dipyridamole / Q000008:administration & dosage / Q000009:adverse effects; D004562:Electrocardiography; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D007262:Infusions, Intravenous / Q000009:adverse effects; D007902:Length of Stay / Q000191:economics; D008991:Monitoring, Physiologic; D009203:Myocardial Infarction / Q000000981:diagnostic imaging* / Q000503:physiopathology; D011877:Radionuclide Imaging; D013794:Thallium Radioisotopes / Q000009:adverse effects*
D013794:Thallium Radioisotopes; D000628:Aminophylline; D004176:Dipyridamole